Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2017

Milestones	Date Met	Payments

(1) when Company initiates a Phase 1 Clinical Trial of a licensed product	July 24, 2012	$	750,000
(2) when Company initiates a Phase 2 Clinical Trial of a licensed product	September __, 2016		750,000
(3) when Company initiates a Phase 3 Clinical Trial of a licensed product	In future		1,500,000
(4) Biological License Application filing with U.S. FDA	In future		1,750,000
(5) First commercial sale	In future		1,500,000
(6) after the first $10,000,000 in net sales	In future		1,500,000
Total		$	7,750,000

For the year ending December 31, 2018			199,440
Total		$	199,440